Tag - LGVN

Developments

Longeveron advances to final phase of XPRISE Healthspan competition

Longeveron (NASDAQ: LGVN) announced that it has been selected from more than 600 worldwide applicants to advance to the final phase of the XPRISE Healthspan competition as a Milestone 2 Awardee team. The $1,000,000...

August 11, 2026

Executive Moves

Longeveron appoints Marie Washburn as CFO

Longeveron (NASDAQ: LGVN) has announced the appointment of Marie Washburn as senior vice president and chief financial officer (CFO), effective July 13, 2026. Ms. Washburn has served as Longeveron’s vice president...

July 7, 2026

Markets

Maxim starts Longeveron at buy; PT $14

Maxim Group initiated coverage of Longeveron (NASDAQ:LGVN) with a “buy” rating and $14 price target. The stock closed at $6.52 on March 23. Longeveron is developing a medicinal signaling cell therapy, Lomecel-B, for...

March 24, 2022

Tag - LGVN

Longeveron advances to final phase of XPRISE Healthspan competition

Longeveron appoints Marie Washburn as CFO

Maxim starts Longeveron at buy; PT $14

Subscribe